Abstract
Driven by the ever-increasing availability of preclinical and clinical Positron Emission Tomography (PET) scanners, the use of non-standard PET nuclides has been growing exponentially in the past decade. Largely complementary to the roles of the four standard PET nuclides (15O, 13N, 11C, and 18F) in PET, non-standard PET nuclides enable the novel design and synthesis of a wider range of PET tracers to probe a variety of biological events. However, characterized by emitting high energy positrons and cascade gamma rays, non-standard PET nuclides with half-lives ranging from seconds to days must be judiciously chosen for specific applications. Generally, chemistries with non-standard PET nuclides are more manageable given a wealth of existing standard operation procedures for the preparation of radiotracers for gamma scintigraphy or Single Photon Emission Computed Tomography (SPECT). This review describes most of the non-standard PET nuclides that have recently been reported for basic PET research or clinical studies with focus on the unique features of their productions, radiochemical procedures, and applications. The main drawbacks of each nuclide are also discussed along with special considerations that must be given towards its practical use in PET.
Keywords: PET, non-standard PET nuclide, imaging probe, immuno-PET, radiation dosimetry, radioimmunoconjugate, molecular imaging
Current Topics in Medicinal Chemistry
Title: PET with Non-Standard Nuclides
Volume: 10 Issue: 11
Author(s): Guiyang Hao, Ajay N Singh, Wei Liu and Xiankai Sun
Affiliation:
Keywords: PET, non-standard PET nuclide, imaging probe, immuno-PET, radiation dosimetry, radioimmunoconjugate, molecular imaging
Abstract: Driven by the ever-increasing availability of preclinical and clinical Positron Emission Tomography (PET) scanners, the use of non-standard PET nuclides has been growing exponentially in the past decade. Largely complementary to the roles of the four standard PET nuclides (15O, 13N, 11C, and 18F) in PET, non-standard PET nuclides enable the novel design and synthesis of a wider range of PET tracers to probe a variety of biological events. However, characterized by emitting high energy positrons and cascade gamma rays, non-standard PET nuclides with half-lives ranging from seconds to days must be judiciously chosen for specific applications. Generally, chemistries with non-standard PET nuclides are more manageable given a wealth of existing standard operation procedures for the preparation of radiotracers for gamma scintigraphy or Single Photon Emission Computed Tomography (SPECT). This review describes most of the non-standard PET nuclides that have recently been reported for basic PET research or clinical studies with focus on the unique features of their productions, radiochemical procedures, and applications. The main drawbacks of each nuclide are also discussed along with special considerations that must be given towards its practical use in PET.
Export Options
About this article
Cite this article as:
Hao Guiyang, N Singh Ajay, Liu Wei and Sun Xiankai, PET with Non-Standard Nuclides, Current Topics in Medicinal Chemistry 2010; 10 (11) . https://dx.doi.org/10.2174/156802610791384289
DOI https://dx.doi.org/10.2174/156802610791384289 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals
Current Topics in Medicinal Chemistry Evolutionary Plasticity of Vertebrate Hox Genes
Current Genomics Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Advances of Metal Enhanced Fluorescence Applications for the Biomedical Field
Current Proteomics Aberrant Lipid Metabolism in Cancer: Current Status and Emerging Therapeutic Perspectives
Current Topics in Medicinal Chemistry Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Current HIV Research HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Development of Precision Medical Technology and its Current Clinical Applications
Recent Patents on Engineering miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Design Graph Theoretical Analysis and In Silico Modeling of Dunaliella Bardawil Biomass Encapsulated N-Succinyl Chitosan Nanoparticles for Enhanced Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery